

Endeavor List Update

No changes to the Endeavor List

Portfolio Strategy

No changes to the Endeavor List

Small caps outperform large cap in December

Small-cap stocks outperformed large cap in December by 763 basis points, with the Russell 2000 Price-Only index up 12.05% versus the S&P 500 Price-Only Index up 4.42%. However, for the full year of 2023, the Russell 2000 Price-Only returned 15.09% versus the S&P 500 Price-Only returning 24.23%. For December, the Endeavor list lagged the Russell 2000 Price-Only benchmark by 169 bps (10.36% versus 12.05%). For the year, the Endeavor List was virtually flat, returning 0.30%.

Description of Endeavor, the small cap buy list

The Endeavor List is a concentrated list of approximately 15-35 small cap stocks that are most compelling using a multi-disciplinary process. Candidates for the Endeavor buy list carry a favorable view by BofA Global Research fundamental equity research analysts and are attractively ranked by our Aurora (growth) or Enhanced Contrarian (value) quantitative models. See page 3 for more details on Endeavor's buy and sell discipline and descriptions of the Aurora and Enhanced Contrarian mode

11 January 2024

Equity and Quant Strategy United States

Research Portfolios

BofAS

Derek Harris Portfolio Strategist +1 646 743 0218

Justin Devery Portfolio Strategist BofAS +1 646 556 2943

Honorat Guidi Portfolio Strategist **BofAS**

+1 646 855 2252

Thomas Hopkins Portfolio Strategist BofAS +1 646 743-6447

Evan Morris Portfolio Strategist **BofAS** +1 646 743 2420

Julia Saravalle, CFA Portfolio Strategist +1 646 855 2155

Shadab Shahzad Ali Portfolio Strategist **BofAS**

+1 646 855 1397

Andrew Shields, CFA Portfolio Strategist +1 646 855 1968

See Team Page for List of Analysts

Trading ideas and investment strategies discussed herein may give rise to significant risk and are not suitable for all investors. Investors should have experience in relevant markets and the financial resources to absorb any losses arising from applying these ideas or strategies.

Bof A Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Refer to important disclosures on page 6 to 8. 12643597

Exhibit 1: Endeavor List Holdings as of 1/11/2024

All prices are as of intraday 1/10/2024

					Mkt				
			BofA	Stock	Value		Enhanced		
GICS Sector	Company	Symbol	Opinion	Price	(\$ Millions)	Aurora	Contrarian	Add Date	Price on Add date
Communication Services	Vivid Seats	SEAT	C-1-9	\$6.20	\$1,284	94	93	11/22/2023	\$7.60
Consumer Discretionary	Penske Auto Group	PAG	B-1-7	\$150.94	\$10,159	74	71	1/7/2019	\$43.88
Consumer Discretionary	Academy	ASO	C-1-7	\$63.35	\$4,745	65	71	4/12/2021	\$30.84
Consumer Discretionary	Group 1 Auto	GPI	C-1-7	\$281.60	\$3,911	96	96	7/18/2023	\$264.93
Consumer Discretionary	Toll Brothers	TOL	B-1-7	\$103.40	\$10,578	97	88	12/20/2023	\$103.61
Consumer Discretionary	Upbound Group	UPBD	C-1-7	\$32.92	\$1,773	97	100	7/18/2023	\$33.37
Energy	Scorpio Tankers	STNG	C-2-7	\$62.04	\$3,364	92	76	7/13/2022	\$32.01
Financials	Flywire	FLYW	C-1-9	\$21.50	\$2,669	88	68	9/21/2023	\$30.27
Financials	PROG Holdings	PRG	C-1-9	\$29.78	\$1,318	98	100	5/5/2023	\$28.73
Financials	Victory Capital	VCTR	B-1-7	\$33.00	\$2,163	62	62	9/21/2023	\$33.22
Health Care	Hims & Hers	HIMS	C-1-9	\$8.51	\$1,810	57	57	11/22/2023	\$7.60
Health Care	Rocket Pharma	RCKT	C-1-9	\$28.82	\$2,653	82	67	12/20/2023	\$28.76
Health Care	Patterson Companies	PDCO	B-1-7	\$29.46	\$2,746	70	90	3/12/2020	\$19.52
Health Care	Select Medical	SEM	B-1-7	\$26.20	\$3,363	69	95	5/5/2023	\$31.40
Industrials	H&E	HEES	C-1-7	\$48.27	\$1,777	92	99	3/14/2023	\$47.07
Industrials	Dycom	DY	B-1-9	\$113.63	\$3,297	83	87	12/20/2023	\$112.41
Industrials	APi Group	APG	B-1-9	\$30.91	\$7,279	79	41	12/20/2023	\$34.02
Industrials	Rush	RUSHA	B-1-7	\$44.72	\$3,630	89	96	7/18/2023	\$61.74
Information Technology	Nutanix	NTNX	C-1-9	\$48.16	\$11,406	95	76	12/20/2023	\$47.08
Information Technology	Jabil Inc.	JBL	B-1-7	\$130.24	\$16,373	90	96	2/4/2021	\$43.20
Information Technology	JFrog	FROG	C-1-9	\$34.02	\$3,468	98	77	6/12/2023	\$25.92
Information Technology	Fastly	FSLY	C-1-9	\$17.55	\$2,299	38	52	8/16/2023	\$18.91
Materials	Berry Global	BERY	B-1-7	\$66.32	\$7,682	70	87	5/5/2020	\$41.78
Materials	O-I Glass Inc	OI	C-1-9	\$15.64	\$2,403	43	92	3/14/2023	\$21.41
Real Estate	Sabra Health Care	SBRA	B-1-7	\$13.77	\$3,170	77	81	10/20/2023	\$14.25

. . .

Source: BofA Global Research; Bloomberg

BofA GLOBAL RESEARCH

Exhibit 2: Endeavor List Performance

All performance numbers are as of 12/31/2023

	Endeavor	Russell 2000
December	10.36%	12.05%
Last three months	6.35%	13.56%
Year to date	0.30%	15.09%
Trailing twelve months	0.30%	15.09%
Annualized Returns		
Trailing three years	0.38%	0.87%
Trailing five years	9.14%	8.50%
Trailing 10 years	5.20%	5.71%
Annualized Since Inception (10/31/97 – 12/31/23)		
Price Return	8.15%	6.10%
Standard Deviation	21.79%	20.81%
Turnover	71.18%	

Source: S&P Compustat, BofA Global Research. Calculation of advances and declines is based on price appreciation or depreciation and reflects additions, deletions (including rebalancings) priced as described in the text describing Performance Calculation Methodology. The calculation does not include dividend or reflect transaction costs. Past performance should not and cannot be viewed as an indicator of future performance. A complete performance record is available upon request. The list identified as Small Cap Endeavor above is intended to be an indicative metric only and may not be used for reference purposes or as a measure of performance for any financial instrument or contract, or otherwise relied upon by third parties for any other purpose, without the prior written consent of BofA Global Research. This list was not created to act as a benchmark.

BofA GLOBAL RESEARCH



Quantitative model methodology

Our quantitative models are an integral part of the Endeavor selection process. Our two proprietary models (Aurora – growth and Enhanced Contrarian – value) are made up of the same three factors but with different weightings to reflect the style characteristics. The goal of the three factors is to capture the sentiment, momentum, and fundamental characteristics of the stocks in the universe and therefore we selected the most effective factors out of these three categories to quantitatively rank stocks. The three factors are estimate revision (sentiment) as defined by a three-month change in the consensus estimates based on I/B/E/S polling. The price momentum factor is based on a 12-month price change and the valuation rank is a sector-adjusted price-to-cash flow (fundamental) analysis. The scores of both models range from 100 (the best possible score) down to 1 (the weakest score), which is calculated based on the contribution of three factors and ranking the companies against the universe based on their raw score. The quantitative scores are calculated on a monthly basis using the Russell indices to determine universe inclusion.

Aurora

The Aurora screen is a combined discipline that takes advantage of successful emerging growth traits, but controls for excess variability. The model ranks companies with better future growth opportunities higher than those that do not, thus having a 70% weight in the sentiment and momentum factors. The construction of the model consists of a 40% weighting in estimate revision, 30% emphasis on relative strength, and 30% weight in sector relative price-to-cash flow.

Enhanced Contrarian

The Enhanced Contrarian screen is a combined discipline that is designed to find stocks with compelling value but removes some of the tendencies of "value traps." The model looks for companies that are undervalued but are strong fundamentally, which is why it places an emphasis on the fundamental factor. The model places a 70% weighting on Price to Cash Flow, a 15% emphasis on estimate revisions, and the remaining 15% on momentum.

Buy & sell discipline

At the time of addition to Endeavor, stocks should satisfy all these conditions:

- Rank favorably in either Aurora or Enhanced Contrarian models, our quantitative models for emerging growth and value investing, respectively. Model ranks range from 1 to 100, with 100 being most favorable.
- Have a favorable fundamental rating of Buy (1) or Neutral (2).
- Are U.S. listed stocks, excluding ADRs, which are smaller companies in the BofA Global Research coverage universe.

Stocks are considered for removal under any one of the following conditions:

- Fundamental, strategic, or tactical reasons at the discretion of the BofA Global Research Portfolios team.
- Comparable stocks become more attractive.
- Ranks in our Aurora or Enhanced Contrarian models deteriorate sharply.
- Fundamental coverage by BofA Global Research is interrupted.
- A stock is downgraded to Neutral from Buy rated.
- The market capitalization of a stock becomes too large for an extended period.



Stocks are removed under either one of the following conditions:

- A stock is downgraded to Underperform.
- Fundamental coverage by BofA Global Research is terminated.
- A stock is delisted.

Performance calculation methodology

The Endeavor price performance is calculated by S&P Compustat. The price performance of an individual security is its percentage change in price, excluding dividends [(End Price – Begin Price)/Begin Price]. The price performance of Endeavor is the weighted performance of all holdings where securities are reset to an equal weighting on the last day of every month. Holdings are also reset to an equal weighting on the date of any announced changes in the recommended list. Therefore, if a change in the recommended list is announced during the month, performance is calculated for the periods before and after the change using an equal weighting of individual security price returns for each respective period. The two periods are then combined to arrive at the monthly returns in the following manner:

$$[(1 + PR1) * (1 + PR2)] - 1$$

Where PR1 is the equal weighted price return of the recommended securities during the period before the announced change and PR2 is the equal weighted price return of the recommended securities during the period after the announced change. Monthly returns are compounded in a similar manner to arrive at the annual returns.

The annualized price return of the Endeavor holdings since inception is calculated using the following formula:

[(1 + Price Return Since Inception) ^ (12/# Months)] -1

Annualized standard deviation, which is presented as a measure of risk, is equal to the standard deviation of monthly price returns since inception times the square root of 12.

Additions and deletions to each of the portfolios (including those resulting from rebalancing changes) were priced as of the market close on the trading day *following* the date that the change was published in a BofA Global Research report. Transactions costs are not included in the performance results.

The performance results of individuals following Endeavor will differ from the performance contained in this report for a variety of reasons, including differences related to recurring transaction costs and/or investment advisory fees as well as the time and price that the stocks were acquired and disposed of, treatment of dividends, and differences in the weighting of such stocks. Investors should also be aware that in constructing and rebalancing their portfolios, we have assumed the ability to purchase fractional shares, though, in fact, fractional shares of these stocks are not available for purchase. In addition, no assurance can be given about future performance results.

The Russell 2000 Index is used as the small cap benchmark for the Endeavor. The Benchmark is comprised of the 2000 stocks having the smallest market capitalization in the Russell 3000 Index. The Russell 2000 is comprised entirely of U.S. stocks.

The Endeavor differs from the Russell 2000 Index in the following ways: (1) The Endeavor considers smaller companies (micro, small and mid-cap shares) in the BofA Global Research coverage universe. As such, stocks in the Endeavor could be larger or smaller than the benchmark at the time of addition. (2) The Endeavor is more exposed to stock-specific risks than the benchmark. As a result of these differences, the Endeavor may experience higher volatility than the benchmark.



Appendix of Returns

Exhibit 3: Quarterly Returns All returns are as of 12/31/2023

Period	Endeavor	Russell 2000
1Q11	11.07%	7.64%
2Q11	5.78%	-1.41%
3Q11	-23.38%	-22.15%
4Q11	14.85%	15.02%
1Q12	10.50%	12.06%
2Q12	-11.04%	-3.83%
3Q12	7.70%	4.88%
4Q12	5.54%	1.42%
1Q13	14.82%	12.03%
2Q13	1.28%	2.73%
3Q13	16.41%	9.85%
4Q13	8.60%	8.37%
1Q14	2.54%	0.81%
2Q14	4.08%	1.70%
3Q14	-6.02%	-7.65%
4Q14	8.46%	9.35%
1Q15	7.10%	3.99%
2Q15	-5.22%	0.09%
3Q15	-15.39%	-12.22%
4Q15	3.82%	3.20%
1Q16	-0.26%	-1.92%
2Q16	-1.18%	1.41%
3Q16	12.72%	8.66%
4Q16	7.10%	8.43%
1Q17	2.22%	2.12%
2Q17	-2.69%	2.12%
3Q17	2.91%	5.33%
4Q17	2.81%	3.00%
1Q18	-0.77%	-0.40%
2Q18	3.67%	7.43%
3Q18	7.77%	3.26%
4Q18	-20.40%	-20.51%
1Q19	19.32%	14.18%
2Q19	2.71%	1.74%
3Q19	-8.34%	-2.76%
4Q19	9.86%	9.52%
1Q20	-28.23%	-30.88%
2Q20	32.00%	25.005
3Q20	8.64%	4.79%
4Q20	21.33%	30.99%
1Q21	10.76%	12.44%
2Q21	5.94%	4.05%
3Q21	-1.69%	-4.60%
4Q21	4.51%	1.86%
1Q22	-3.36%	-7.80%
2Q22	-19.52%	-17.49%
3Q22	-0.81%	-2.53%
4Q22	8.45%	5.80%
1Q23	0.97%	2.34%
2Q23	2.23%	4.79%
3Q23	-8.64%	-5.49%
Source: BofA Glob	bal Research; S&P Compustat. Past perfo	rmance should not and canno

urce: BofA Global Research; S&P Compustat. Past performance should not and cannot be viewed as an indicator of future performance.

BofA GLOBAL RESEARCH

Exhibit 4: Historical Returns All returns are as of 12/31/2023

Period	Endeavor	Russell 2000
2004	15.30%	17.00%
2005	-1.40%	3.30%
2006	-0.50%	17.00%
2007	12.10%	-2.70%
2008	-35.60%	-34.80%
2009	42.90%	25.20%
2010	26.50%	25.30%
2011	3.40%	-5.00%
2012	11.70%	14.60%
2013	47.00%	37.00%
2014	8.80%	3.50%
2015	-10.80%	-5.70%
2016	19.00%	19.50%
2017	5.25%	13.14%
2018	-11.70%	-12.18%
2019	23.41%	23.72%
2020	24.02%	18.36%
2021	20.51%	13.70%
2022	-16.35%	-21.56%
2023	0.30%	15.09%

Source: BofA Global Research; S&P Compustat. Past performance should not and cannot be viewed as an indicator of future performance.

BofA GLOBAL RESEARCH

Disclosures

Important Disclosures

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperformstocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating Total return expectation (within 12-month period of date of initial rating) Ratings dispersion guidelines for coverage cluster^{R1}

Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Underperform	N/A	≥ 20%

Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: Academy, APi Group, Berry Global, Dycom, Fastly, Flywire, Group 1 Auto, H&E, Hims & Hers, Jabil Inc., JFrog, Nutanix, O-I Glass Inc, Patterson Companies, Penske Auto Group, PROG Holdings, Rocket Pharma, Rush, Sabra Health Care, Scorpio Tankers, Select Medical, Toll Brothers, Upbound Group, Victory Capital, Vivid Seats.

BofAS or an affiliate was a manager of a public offering of securities of this issuer within the last 12 months: Flywire, Jabil Inc., SEAT.

The issuer is or was, within the last 12 months, an investment banking client of BofAS and/or one or more of its affiliates: APi Group, Berry Global, Dycom Inds, Fastly, Flywire, H&E Equipment Servic, Jabil Inc., Patterson Companies, Sabra Health Care, SEAT, Select Medical, Toll Brothers, Inc., Victory Capital.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: Academy Sports + Out, APi Group, Berry Global, Dycom Inds, Fastly, Flywire, Group 1 Automoti, H&E Equipment Servic, Hims & Hers, Jabil Inc., Nutanix Inc, Patterson Companies, Penske Auto Group, PROG Holdings, Rush, Sabra Health Care, SEAT, Select Medical, Toll Brothers, Inc., Upbound Group, Victory Capital.

The issuer is or was, within the last 12 months, a non-securities business client of BofAS and/or one or more of its affiliates: Academy Sports + Out, APi Group, Berry Global, Dycom Inds, Fastly, Flywire, Group 1 Automoti, H&E Equipment Servic, Hims & Hers, Jabil Inc., Nutanix Inc, Patterson Companies, Penske Auto Group, PROG Holdings, Rush, Sabra Health Care, SEAT, Select Medical, Toll Brothers, Inc., Upbound Group, Victory Capital.

BofAS or an affiliate has received compensation for investment banking services from this issuer within the past 12 months: Berry Global, Flywire, H&E Equipment Servic, Jabil Inc., Patterson Companies, Sabra Health Care, SEAT, Select Medical, Toll Brothers, Inc., Victory Capital.

BofAS or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer or an affiliate of the issuer within the next three months: APi Group, Berry Global, Dycom Inds, Fastly, Jabil Inc., Victory Capital.

BofAS together with its affiliates beneficially owns one percent or more of the common stock of this issuer. If this report was issued on or after the 9th day of the month, it reflects the ownership position on the last day of the previous month. Reports issued before the 9th day of a month reflect the ownership position at the end of the second month preceding the date of the report: Academy Sports + Out, Berry Global, Dycom Inds, Fastly, Group 1 Automoti, H&E Equipment Servic, Hims & Hers, Jabil Inc., JFrog, O-I Glass Inc, Patterson Companies, PROG Holdings, Rush, Sabra Health Care, Scorpio Tankers Inc., SEAT, Upbound Group, Victory Capital.

BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: Academy, APi Group, Berry Global, Dycom, Fastly, Flywire, Group 1 Auto, H&E, Hims & Hers, Jabil Inc., JFrog, Nutanix, O-I Glass Inc, Patterson Companies, Penske Auto Group, PROG Holdings, Rocket Pharma, Rush, Sabra Health Care, Scorpio Tankers, Select Medical, Toll Brothers, Upbound Group, Victory Capital, Vivid Seats.

The issuer is or was, within the last 12 months, a securities business client (non-investment banking) of BofAS and/or one or more of its affiliates: APi Group, Berry Global, Dycom Inds, Flywire, Group 1 Automoti, Hims & Hers, Jabil Inc., Nutanix Inc, Patterson Companies, Penske Auto Group, PROG Holdings, Rush, Sabra Health Care, Toll Brothers, Inc., Victory Capital. Due to the nature of strategic analysis, the issuers or securities recommended or discussed in this report are not continuously followed. Accordingly, investors must regard this report as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or securities.

Due to the nature of quantitative analysis, the issuers or securities recommended or discussed in this report are not continuously followed. Accordingly, investors must regard this report as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or securities.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.

Other Important Disclosures

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments. Refer to BofA Global Research policies relating to conflicts of interest.

'BofA Securities' includes BofA Securities, Inc. ('BofAS') and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. 'BofA Securities' is a



global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofASEdisclaimer; BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI), BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI, BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch (Canada): Merrill Lynch (Canada): Merrill Lynch (Mexico): Mexico): Merrill Lynch (Mexico): Mexico): Merrill Lynch (Mexico): Mexico): Mexico (Mexico): Mexico (Mexico de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to "Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securit

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond

the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

BofA ESGMeter Methodology:

ESGMeter is a proprietary metric based on quantitative analysis and fundamental analyst inputs that reflects our assessment of a company's Environmental, Social and Governance-related attributes. The ESGMeter is intended to indicate a company's likelihood of experiencing stronger financial stability (higher return on equity and lower earnings and price volatility) over the next three years relative to peer group. There are three ESGMeter levels - Low, Medium, and High - which indicate whether a company has attributes most likely to translate into superior financial stability (in the case of a High level) or weaker financial stability (in the case of a Low level) over the next three years relative to its peer group. A Medium level suggests that a company exhibits ESG characteristics that are likely associated with financial stability results in line with its peer group over the next three years. Full details of our methodology, financial stability definition and disclaimers are available at BofA ESGMeter methodology. ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of the BofA Global Research fundamental equity analyst's investment rating, volatility risk rating, income rating or price objective for that company.

Copyright 2024 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants, co-defendants, or co-plaintiffs with or involving issuers mentioned in this material is based

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.



Research Analysts

Research Portfolios

Derek Harris

Portfolio Strategist BofAS +1 646 743 0218 derek.harris@bofa.com

Justin Devery
Portfolio Strategist
BofAS
+1 646 556 2943

justin.devery@bofa.com **Evan Morris** Portfolio Strategist

BofAS +1 646 743 2420 evan.morris@bofa.com

Thomas Hopkins Portfolio Strategist BofAS +1 646 743-6447 thopkins2@bofa.com

Andrew Shields, CFA
Portfolio Strategist
BofAS
+1 646 855 1968

andrew.shields@bofa.com

Julia Saravalle, CFA

Portfolio Strategist BofAS +1 646 855 2155 julia.saravalle@bofa.com

Shadab Shahzad Ali Portfolio Strategist BofAS +1 646 855 1397 shadab.ali@bofa.com

Honorat Guidi Portfolio Strategist BofAS +1 646 855 2252 honorat.guidi@bofa.com

Trading ideas and investment strategies discussed herein may give rise to significant risk and are not suitable for all investors. Investors should have experience in relevant markets and the financial resources to absorb any losses arising from applying these ideas or strategies.

